Ventoux Biosciences

Ventoux Biosciences is a San Diego-based biopharmaceutical company pioneering first-line, disease-modifying therapies for Dupuytren’s disease and related fibrotic conditions. Founded in 2022 by a patient with over 25 years in the pharmaceutical industry, Ventoux is advancing VEN-201, an investigational treatment showing promising anti-fibrotic effects in preclinical studies. The company’s mission is to provide innovative, non-surgical options for millions affected by these chronic, progressive diseases.